Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab
Opel, D.; Economidi, A.; Chan, D.; Wasfi, Y.; Mistry, S.; Vergou, T.; Antoniou, C.; Sofen, H.
Journal of Drugs in Dermatology Jdd 11(12): 1498-1501
2012
ISSN/ISBN: 1545-9616 PMID: 23377523 Document Number: 15886
Patients with psoriasis who are treated with systemic and biologic therapies may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that modulate CD4+ T cell subsets, including interleukin (IL)-12 and IL-23, have been suggested to play a role in the pathogenesis of HBV infection. To report the first known cases of acute HBV infection in 2 ustekinumab-treated patients with psoriasis from a phase 3 (PHOENIX 1) and a phase 4 (TRANSIT) study. Both ustekinumab-treated patients generated an immune response toward HBV and experienced typical courses of infection, without progression to chronic HBV infection. Continued monitoring of liver-related adverse events in clinical trials, registries, and spontaneous reporting from the postmarketing setting will further contribute to understanding the role of ustekinumab in viral hepatitis.
Document emailed within 1 workday
